EP3914251A4 - N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors - Google Patents

N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors Download PDF

Info

Publication number
EP3914251A4
EP3914251A4 EP20895135.0A EP20895135A EP3914251A4 EP 3914251 A4 EP3914251 A4 EP 3914251A4 EP 20895135 A EP20895135 A EP 20895135A EP 3914251 A4 EP3914251 A4 EP 3914251A4
Authority
EP
European Patent Office
Prior art keywords
benzamides
phenylsulfonyl
bcl
inhibitors
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20895135.0A
Other languages
German (de)
French (fr)
Other versions
EP3914251A1 (en
Inventor
Yifan Zhai
Dajun Yang
Zi CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascentage Pharma Suzhou Co Ltd
Ascentage Pharma Group Co Ltd
Original Assignee
Ascentage Pharma Suzhou Co Ltd
Ascentage Pharma Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma Suzhou Co Ltd, Ascentage Pharma Group Co Ltd filed Critical Ascentage Pharma Suzhou Co Ltd
Publication of EP3914251A1 publication Critical patent/EP3914251A1/en
Publication of EP3914251A4 publication Critical patent/EP3914251A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
EP20895135.0A 2019-12-03 2020-12-03 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors Pending EP3914251A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2019122608 2019-12-03
CN2020078364 2020-03-09
CN2020095844 2020-06-12
CN2020100903 2020-07-08
CN202011352984 2020-11-27
PCT/CN2020/133621 WO2021110097A1 (en) 2019-12-03 2020-12-03 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (2)

Publication Number Publication Date
EP3914251A1 EP3914251A1 (en) 2021-12-01
EP3914251A4 true EP3914251A4 (en) 2022-03-23

Family

ID=76111461

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20895135.0A Pending EP3914251A4 (en) 2019-12-03 2020-12-03 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Country Status (5)

Country Link
US (1) US20220305034A1 (en)
EP (1) EP3914251A4 (en)
CN (1) CN112898295A (en)
TW (1) TWI772992B (en)
WO (1) WO2021110097A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125241C2 (en) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/orbendamustine or bcl-2 inhibitor combined with chop
JP2023539114A (en) * 2020-08-21 2023-09-13 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Compositions and methods for treating systemic lupus erythematosus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040617A1 (en) * 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3179991T3 (en) * 2014-08-11 2022-02-14 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
AU2016314082B2 (en) * 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
EP4129999A1 (en) 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
UA125241C2 (en) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/orbendamustine or bcl-2 inhibitor combined with chop
AU2019314819A1 (en) * 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN110772521A (en) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2 inhibitor or Bcl-2/Bcl-xL inhibitor and BTK inhibitor combination product and application thereof
KR20210003731A (en) * 2018-07-31 2021-01-12 어센테지 파마 (쑤저우) 컴퍼니 리미티드 Combination products of Bcl-2 inhibitor and MDM2 inhibitor and their use in the prevention and/or treatment of diseases
WO2020103921A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040617A1 (en) * 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARINA KONOPLEVA ET AL: "Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia", CANCER DISCOVERY, vol. 6, no. 10, 12 August 2016 (2016-08-12), US, pages 1106 - 1117, XP055642391, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-16-0313 *
See also references of WO2021110097A1 *

Also Published As

Publication number Publication date
TWI772992B (en) 2022-08-01
TW202133848A (en) 2021-09-16
CN112898295A (en) 2021-06-04
WO2021110097A1 (en) 2021-06-10
US20220305034A1 (en) 2022-09-29
EP3914251A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL282099B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3788042A4 (en) Bcl-2 inhibitors
EP4051676A4 (en) Bcl-2 inhibitors
EP3741374A4 (en) Mtor inhibitor, pharmaceutical composition and use thereof
EP3938369A4 (en) Tyk2 inhibitors and uses thereof
EP3914357A4 (en) Tyk2 inhibitors and uses thereof
EP3950685A4 (en) Pyrazolopyridine compound as ret inhibitor and application thereof
EP4003319A4 (en) Hdac6 inhibitors and uses thereof
EP3972966A4 (en) Bcl-2 protein inhibitors
EP3877381A4 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3969439A4 (en) Acss2 inhibitors and methods of use thereof
EP3986894A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP4107152A4 (en) Bcl-2 protein inhibitors
EP3851440A4 (en) Cyclopropylamine compound as lsd1 inhibitor and use thereof
EP3760628A4 (en) Peptidylarginine deiminase inhibitor and use thereof
EP3914251A4 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3784650A4 (en) Novel mct4 inhibitors and uses thereof
EP3880671A4 (en) Novel compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof
EP3958867A4 (en) Small molecule bromodomain inhibitors and uses thereof
EP3967696A4 (en) Compound used as kinase inhibitor and application thereof
EP3982968A4 (en) Hdac3 catalytic inhibitor development and uses thereof
EP3972601A4 (en) Nanoparticle formulation of bcl-2 inhibitor
EP3995134A4 (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
EP3941909A4 (en) Pi4-kinase inhibitors and methods of using the same
EP3774708A4 (en) Foxm1 inhibitor compositions and methods of using the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031497000

Ipc: A61K0031496000

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20220221

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20220215BHEP

Ipc: A61P 35/02 20060101ALI20220215BHEP

Ipc: A61P 35/00 20060101ALI20220215BHEP

Ipc: A61K 45/06 20060101ALI20220215BHEP

Ipc: A61K 31/706 20060101ALI20220215BHEP

Ipc: A61K 31/55 20060101ALI20220215BHEP

Ipc: A61K 31/519 20060101ALI20220215BHEP

Ipc: A61K 31/497 20060101ALI20220215BHEP

Ipc: A61K 31/4745 20060101ALI20220215BHEP

Ipc: A61K 31/454 20060101ALI20220215BHEP

Ipc: A61K 31/496 20060101AFI20220215BHEP

Ipc: A61K 31/573 20060101ALI20220215BHEP

17Q First examination report despatched

Effective date: 20220318

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230726